Last edition
News about "KVA12123 anti-VISTA antibody"
TuHURA Biosciences Signs Exclusivity and Right of First Offer Deal for Kineta
TuHURA Biosciences, Inc. has entered into an Exclusivity and Right of First Offer Agreement with Kineta, Inc. for the potential acquisition of Kineta's KVA12123 anti-VISTA antibody and related rights and assets associated with and derived from the asset.
KVA12123 Anti-VISTA Antibody | 09/07/2024 | By Aishwarya | 457
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members